FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361945913> ?p ?o ?g. }

• W4361945913 abstract "<div>Abstract<p><b>Purpose:</b> Non–small cell lung cancers (NSCLCs) harboring <i>ALK</i> gene rearrangements (ALK⁺) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary resistance mutations in ALK or disease progression in the brain. Mutations that confer resistance to second-generation ALK TKIs ceritinib and alectinib have also been identified. Here, we report the structure and first comprehensive preclinical evaluation of the next-generation ALK TKI brigatinib.</p><p><b>Experimental Design:</b> A kinase screen was performed to evaluate the selectivity profile of brigatinib. The cellular and <i>in vivo</i> activities of ALK TKIs were compared using engineered and cancer-derived cell lines. The brigatinib–ALK co-structure was determined.</p><p><b>Results:</b> Brigatinib potently inhibits ALK and ROS1, with a high degree of selectivity over more than 250 kinases. Across a panel of ALK⁺ cell lines, brigatinib inhibited native ALK (IC₅₀, 10 nmol/L) with 12-fold greater potency than crizotinib. Superior efficacy of brigatinib was also observed in mice with ALK⁺ tumors implanted subcutaneously or intracranially. Brigatinib maintained substantial activity against all 17 secondary ALK mutants tested in cellular assays and exhibited a superior inhibitory profile compared with crizotinib, ceritinib, and alectinib at clinically achievable concentrations. Brigatinib was the only TKI to maintain substantial activity against the most recalcitrant ALK resistance mutation, G1202R. The unique, potent, and pan-ALK mutant activity of brigatinib could be rationalized by structural analyses.</p><p><b>Conclusions:</b> Brigatinib is a highly potent and selective ALK inhibitor. These findings provide the molecular basis for the promising activity being observed in ALK⁺, crizotinib-resistant patients with NSCLC being treated with brigatinib in clinical trials. <i>Clin Cancer Res; 22(22); 5527–38. ©2016 AACR</i>.</p></div>" @default.
• W4361945913 created "2023-04-05" @default.
• W4361945913 creator A5000075307 @default.
• W4361945913 creator A5004723852 @default.
• W4361945913 creator A5004778927 @default.
• W4361945913 creator A5005199804 @default.
• W4361945913 creator A5007400441 @default.
• W4361945913 creator A5008040654 @default.
• W4361945913 creator A5020483894 @default.
• W4361945913 creator A5027538058 @default.
• W4361945913 creator A5028196907 @default.
• W4361945913 creator A5030594054 @default.
• W4361945913 creator A5030692726 @default.
• W4361945913 creator A5032535992 @default.
• W4361945913 creator A5037774305 @default.
• W4361945913 creator A5040083297 @default.
• W4361945913 creator A5056126777 @default.
• W4361945913 creator A5060754365 @default.
• W4361945913 creator A5061990577 @default.
• W4361945913 creator A5063781367 @default.
• W4361945913 creator A5066578495 @default.
• W4361945913 creator A5068862707 @default.
• W4361945913 creator A5077797768 @default.
• W4361945913 creator A5077932736 @default.
• W4361945913 creator A5078494293 @default.
• W4361945913 creator A5078519407 @default.
• W4361945913 creator A5083951706 @default.
• W4361945913 creator A5084547756 @default.
• W4361945913 creator A5090562312 @default.
• W4361945913 date "2023-03-31" @default.
• W4361945913 modified "2023-09-24" @default.
• W4361945913 title "Data from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models" @default.
• W4361945913 doi "https://doi.org/10.1158/1078-0432.c.6525524" @default.
• W4361945913 hasPublicationYear "2023" @default.
• W4361945913 type Work @default.
• W4361945913 citedByCount "0" @default.
• W4361945913 crossrefType "posted-content" @default.
• W4361945913 hasAuthorship W4361945913A5000075307 @default.
• W4361945913 hasAuthorship W4361945913A5004723852 @default.
• W4361945913 hasAuthorship W4361945913A5004778927 @default.
• W4361945913 hasAuthorship W4361945913A5005199804 @default.
• W4361945913 hasAuthorship W4361945913A5007400441 @default.
• W4361945913 hasAuthorship W4361945913A5008040654 @default.
• W4361945913 hasAuthorship W4361945913A5020483894 @default.
• W4361945913 hasAuthorship W4361945913A5027538058 @default.
• W4361945913 hasAuthorship W4361945913A5028196907 @default.
• W4361945913 hasAuthorship W4361945913A5030594054 @default.
• W4361945913 hasAuthorship W4361945913A5030692726 @default.
• W4361945913 hasAuthorship W4361945913A5032535992 @default.
• W4361945913 hasAuthorship W4361945913A5037774305 @default.
• W4361945913 hasAuthorship W4361945913A5040083297 @default.
• W4361945913 hasAuthorship W4361945913A5056126777 @default.
• W4361945913 hasAuthorship W4361945913A5060754365 @default.
• W4361945913 hasAuthorship W4361945913A5061990577 @default.
• W4361945913 hasAuthorship W4361945913A5063781367 @default.
• W4361945913 hasAuthorship W4361945913A5066578495 @default.
• W4361945913 hasAuthorship W4361945913A5068862707 @default.
• W4361945913 hasAuthorship W4361945913A5077797768 @default.
• W4361945913 hasAuthorship W4361945913A5077932736 @default.
• W4361945913 hasAuthorship W4361945913A5078494293 @default.
• W4361945913 hasAuthorship W4361945913A5078519407 @default.
• W4361945913 hasAuthorship W4361945913A5083951706 @default.
• W4361945913 hasAuthorship W4361945913A5084547756 @default.
• W4361945913 hasAuthorship W4361945913A5090562312 @default.
• W4361945913 hasConcept C117643217 @default.
• W4361945913 hasConcept C121608353 @default.
• W4361945913 hasConcept C126322002 @default.
• W4361945913 hasConcept C185592680 @default.
• W4361945913 hasConcept C2775999482 @default.
• W4361945913 hasConcept C2776232967 @default.
• W4361945913 hasConcept C2776256026 @default.
• W4361945913 hasConcept C2778347629 @default.
• W4361945913 hasConcept C2779220645 @default.
• W4361945913 hasConcept C2779422266 @default.
• W4361945913 hasConcept C2779750558 @default.
• W4361945913 hasConcept C2781182431 @default.
• W4361945913 hasConcept C42362537 @default.
• W4361945913 hasConcept C502942594 @default.
• W4361945913 hasConcept C55493867 @default.
• W4361945913 hasConcept C62478195 @default.
• W4361945913 hasConcept C71924100 @default.
• W4361945913 hasConcept C98274493 @default.
• W4361945913 hasConceptScore W4361945913C117643217 @default.
• W4361945913 hasConceptScore W4361945913C121608353 @default.
• W4361945913 hasConceptScore W4361945913C126322002 @default.
• W4361945913 hasConceptScore W4361945913C185592680 @default.
• W4361945913 hasConceptScore W4361945913C2775999482 @default.
• W4361945913 hasConceptScore W4361945913C2776232967 @default.
• W4361945913 hasConceptScore W4361945913C2776256026 @default.
• W4361945913 hasConceptScore W4361945913C2778347629 @default.
• W4361945913 hasConceptScore W4361945913C2779220645 @default.
• W4361945913 hasConceptScore W4361945913C2779422266 @default.
• W4361945913 hasConceptScore W4361945913C2779750558 @default.
• W4361945913 hasConceptScore W4361945913C2781182431 @default.
• W4361945913 hasConceptScore W4361945913C42362537 @default.
• W4361945913 hasConceptScore W4361945913C502942594 @default.
• W4361945913 hasConceptScore W4361945913C55493867 @default.
• W4361945913 hasConceptScore W4361945913C62478195 @default.
• W4361945913 hasConceptScore W4361945913C71924100 @default.
• W4361945913 hasConceptScore W4361945913C98274493 @default.

• next